**Virologica Sinica**

**Supplementary Data**

**Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum**

Yuqi Zhu a, Xinyi Yang a, Jingna Xun a, b, Jun Liu a, c, Qing Wen a, Yixiao Lin d, Xiaoting Shen a, Jun Chen d, Songhua Yuan b, Xiaying Zhao a, Jing Wang a, Hanyu Pan a, Jinlong Yang a, Zhiming Liang a, Yue Liang a, Qinru Lin a, Huitong Liang a, Min Lia Jianping Liu a, Yinzhong Shen b, Xiaoyan Zhang b, Pengfei Wang a, Daru Lu a,Chunhua Yin a, Jianqing Xu b, Shibo Jiang e , Hongzhou Lu b, d, f, \*, Huanzhang Zhu a, \*

a State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China

b Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508 China

c Fubio (Suzhou) Biomedical Technology Co., Ltd, Suzou 215300, China

d Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China

e. Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

f. Department of Infectious Diseases and Nursing research institution, National Clinical Research Center for Infectious Diseases, The Third People's Hospital of Shenzhen , Shenzhen 518112, China.

**\*Corresponding authors**

E-mail addresses: hzzhu@fudan.edu.cn (H, Zhu); luhongzhou@fudan.edu.cn (H. Lu).

ORCID: 0000-0001-5797-0292 (H, Zhu); 0000-0002-8308-5534 (H, Lu)

Supplementary Table S1 Characteristics of study subjects

|  |
| --- |
| Characteristics of study subjects |
| Characteristics | COVID-19 convalescents | BBIBP-CorV vaccinees |
| Number of volunteers | 10 | 10 |
| Age, median (range) | 53 (33-68) | 36 (22-56) |
| Gender | 　 |
| Male (%) | 4 (40%) | 5 (50%) |
| Female (%) | 6 (60%) | 5 (50%) |
| 1st blood sampling interval, median (range)  | 14.5 (9-19) | 37.5 (19-47) |
| 2nd blood sampling interval, median (range)  | 200.5 (189-229) | 91 (75-100) |
| 3rd blood sampling interval, median (range)  | NA | 150.6 (135-160) |
| Clinical classification | 　 |
| Severe | 1 | NA |
| Non-severe | 9 | NA |
| Note: Age, gender, sampling interval, clinical diagnostic information and status of reinfection were included for 10 convalescents and 10 vaccinees. |
|